Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Betahistine”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources
PubMed1978

Modification of the size of developing infarcts in the ligated dog heart by betahistine-HCL.

The effectiveness of beta-histine-HCL in modifying the size of developing myocardial infarcts was tested in the surgically ligated dog. Branches of the left coronary artery were ligated and a 6-hour continuous intravenous infusion of 0.24 mg/kg/min of beta-histine was administered from 0 to 120 min after ligation. The effect of this treatment was evaluated histologically in studies on acute ischemia by the use of the hematoxylin-basic fuchsin-picric acid stain for early myocardial ischemia. The treatment was also evaluated grossly in a study on chronic ischemia where the dogs were permitted to survive for 30 days before sacrifice. In these experiments the size of infarcts found in the beta-histine-treated animals was compared with those found in the saline controls. Both studies showed that the control ligations produced a large uniform area of ischemia or infarction that was greatly reduced or prevented by immediate treatment with beta-histine. Also, beta-histine was capable of significantly reducing the size of developing infarcts for up to 120 min after ligation.

Animals↗
PubMed1996

Nonpigmenting fixed drug eruption: a new case due to betahistine.

We describe a new case of a seldom reported subset of fixed drug eruption, the nonpigmenting type. Aside from their fixed nature and their well-demarcated margins, pigmenting and non-pigmenting subsets of fixed drug eruption exhibit well-separated clinical and histological features allowing easy recognition. The precise physiopathology is currently unknown in both conditions, but a delayed hypersensitivity mechanism is likely. The nature of the inducing drugs of the nonpigmenting eruption is discussed.

Betahistine↗
PubMedDate not supplied

[Electronystagmography study in patients with the insufficiency of vertebrobasilar artery after betahistine treatment].

The aim of the study was objective assessment of the results of betahistyne treatment in patients with chronic insufficiency of the vertebrobasilar artery system by means of elektronystagmography (ENG). The patients had mostly vertigo and/or dizziness, headache, ear buzzing and disequilibrium sensations. In 46 patients clinical, audiological and ENG examinations were carried out. All symptoms decreased in frequency after the treatment. Vertigo and/or dizziness improvement was noted in 58.5% patients of cases, headache decreased in 56.5% of cases, ear buzzing decreased in 42.8% and hearing improved in 22.2%. Before treatment 76% of patients had pathologic changes in ENG, after treatment improvement of ENG was noted in all tests, particularly in 17 cases (48.6%). This was most frequent in spontaneous nystagmus (83%), positional test (85%), caloric test (83%), and optokinetic test (71%). Comparison of complaints and ENG findings before and after treatment showed improvement both in symptoms and signs. Betaserc was effective in the treatment of patients with vertebrobasilar system insufficiency both in subjective opinions of patients and in objective assessment by ENG.

Aged↗